Lipid improvements with GLP-1 agonists tend to reverse after discontinuation due to weight regain, which is worth considering when discussing them as alternatives to statins
J Inherit.Metab Dis 2008;31 Suppl 2:S453-S456
2023;72(Supplement_1)
Without FDA approval, prescribing such a substance could be considered malpractice, risking their licenses and legal action

Get the Injury, Joint & Recovery Blueprint *Educational only No protocols Written by clinicians* When to Use BPC-157 + TB-500 This blend is ideal for a range of patients and scenarios, including: Athletes looking to recover from training faster Post-surgical patients needing accelerated healing Individuals with tendinopathy , ligament sprains , or joint instability Chronic pain sufferers seeking regenerative alternatives Patients with gut inflammation or leaky gut (BPC-157 has GI-healing properties) People with connective tissue disorders or injury-prone joints Individuals experiencing inflammatory joint conditions (such as arthritis) Expected Results While every patient responds differently, many experience: Reduced pain and inflammation within 12 weeks Enhanced range of motion and tissue resilience Accelerated recovery time from injuries or surgeries Improved mobility and flexibility Reduced gut permeability and inflammation (via BPC-157) Peak results are typically seen 48 weeks into therapy, depending on severity and dosing

for 21 days on a twice-daily schedule with 100 mg/kg lapatinib alone before PBS administration (5 animals)